ALEXANDER'S INC. DL 1 Logo
US0147521092

ALEXANDER'S INC. DL 1

Ins Portfolio
60% Chancen, 40% Gelassenheit. Aktien und Anleihen in einem LifeStrategy ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

 Anzeige

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +111,97(43,31%). Der Median liegt bei +111,97(43,31%).

Kaufen
  1
Halten
  0
Verkaufen
  1

Scoring-Modelle

Dividenden-Strategie9 / 15
HGI-Strategie3 / 18
Levermann-Strategie-3 / 13
Powered byaktien.guide

News

  • Foto von ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

    ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

    SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year.» Mehr auf globenewswire.com

  • Foto von All You Need to Know About Alexander's (ALX) Rating Upgrade to Strong Buy

    All You Need to Know About Alexander's (ALX) Rating Upgrade to Strong Buy

    Alexander's (ALX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.» Mehr auf zacks.com

  • Foto von ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

    ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20 Company will not pursue U.S. registrational path in gastric cancer following receipt of FDA feedback that accelerated approval pathway is not feasible based on ASPEN-06 due to standard-of-care evolving to ENHERTU® Data milestones expected across Company's three clinical programs in 2026 Cash runway has been extended into Q4 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) --  ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.» Mehr auf globenewswire.com

Dividenden

Alle Kennzahlen
In 2025 hat ALEXANDER'S INC. DL 1 bereits +4,34 Dividende ausgeschüttet. Die letzte Dividende wurde im Februar gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte ALEXANDER'S INC. DL 1 einen Umsatz von +50,76 Mio und ein Nettoeinkommen von +11,38 Mio
(EUR)März 2025
YOY
Umsatz+50,76 Mio10,77%
Bruttoeinkommen+27,13 Mio18,97%
Nettoeinkommen+11,38 Mio23,75%
EBITDA+30,04 Mio6,47%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+1,01 Mrd
Anzahl Aktien
5,11 Mio
52 Wochen-Hoch/Tief
+225,41 - +165,51
Dividendenrendite
+8,51%
Dividenden TTM
+16,80
Nächste Dividende
+4,03
Beta
0,74
KGV (PE Ratio)
+28,58
KGWV (PEG Ratio)
3,27
KBV (PB Ratio)
0,00
KUV (PS Ratio)
+5,13

Unternehmensprofil

Alexander's, Inc. ist ein Immobilien-Investment-Trust, der sieben Immobilien im Großraum New York City besitzt.

Name
ALEXANDER'S INC. DL 1
CEO
Steven Roth
SitzParamus, nj
USA
Website
Industrie
Diversifizierte REITs
Börsengang
Mitarbeiter90

Ticker Symbole

BörseSymbol
NYSE
ALX
Frankfurt
AXE.F
Düsseldorf
AXE.DU
München
AXE.MU
🍪

Parqet nutzt Cookies.Erfahre Mehr